To the Editor: The MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial) II investigators1 have shown that pyridoxal 5"-phosphate monohydrate (MC-1) did not reduce cardiovascular death or nonfatal myocardial infarction (MI) in intermediate- to high-risk patients undergoing coronary artery bypass graft (CABG) surgery. According to their data, there were no significant differences in concomitant medical therapies during hospitalization between the MC-1 and placebo groups (Table 4).
Oh J, Hong N, Kang S. Clopidogrel Treatment and the MEND-CABG II Trial. JAMA. 2008;300(9):1021–1022. doi:10.1001/jama.300.9.1021-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: